^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | palazestrant (OP-1250) (Estrogen receptor antagonist, Selective estrogen receptor degrader) |
| Drug Class: | HER2 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The complete estrogen receptor antagonist OP-1250 can combine with HER2 inhibition to inhibit estrogen receptor-driven cellular proliferation and shrink xenograft tumors in ER+/HER2+ breast cancer models
Published date:
10/09/2021
Excerpt:
The addition of OP-1250 to a HER2 inhibitor also resulted in greater tumor shrinkage in multiple ER+/HER2+ xenograft models. Our data suggests a potential clinical benefit in the addition of OP-1250 on top of HER2 inhibition for the treatment of ER+/HER2+ breast cancer...
